These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37184523)
21. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930 [TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384 [TBL] [Abstract][Full Text] [Related]
23. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727 [TBL] [Abstract][Full Text] [Related]
24. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Hegade VS; Pechlivanis A; McDonald JAK; Rees D; Corrigan M; Hirschfield GM; Taylor-Robinson SD; Holmes E; Marchesi JR; Kendrick S; Jones DE Liver Int; 2019 May; 39(5):967-975. PubMed ID: 30735608 [TBL] [Abstract][Full Text] [Related]
25. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937 [TBL] [Abstract][Full Text] [Related]
26. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. Sokol RJ; Gonzales EM; Kamath BM; Baker A; Vig P; Mogul DB; Garner W; Hansen BE; Jacquemin E; Thompson RJ Hepatology; 2023 Dec; 78(6):1698-1710. PubMed ID: 37278241 [TBL] [Abstract][Full Text] [Related]
27. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Epstein MP; Kaplan MM Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426 [TBL] [Abstract][Full Text] [Related]
28. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Tabibian JH; Gossard A; El-Youssef M; Eaton JE; Petz J; Jorgensen R; Enders FB; Tabibian A; Lindor KD Am J Ther; 2017; 24(1):e56-e63. PubMed ID: 24914504 [TBL] [Abstract][Full Text] [Related]
29. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864 [TBL] [Abstract][Full Text] [Related]
30. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome. Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ; Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis. Liu X; Wang H; Liu X; Bridle K; Crawford D; Liang X Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884 [TBL] [Abstract][Full Text] [Related]
32. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038 [TBL] [Abstract][Full Text] [Related]
33. Novel Aspects in the Management of Cholestatic Liver Diseases. Chazouillères O Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387 [TBL] [Abstract][Full Text] [Related]